$EXEL

Exelixis, Inc. presented at the Leerink Global Healthcare Conference 2026, discussing their innovative therapies and pipeline advancements. The presentation was well-received, highlighting strong data supporting their clinical trials and strategic partnerships. Investors showed optimism due to the potential for future growth and revenue generation in the oncology sector. Market reaction appears positive, with analysts revisiting their price targets for EXEL. Overall, the conference presence may bolster investor confidence as Exelixis aims for deeper market penetration.